SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CABA reported Third Quarter 2026 results. The price and volatility reaction is pending.
CABAearnings

Earnings reactions, page 6

Cabaletta Bio, Inc. (CABA) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $47.1 million for the three months ended September 30, 2026, compared to $39.8 million for the same period in 2025.
  • General and administrative expenses were $7.6 million for the three months ended September 30, 2026, compared to $6.8 million for the same period in 2025.
  • Net loss was $53.1 million for the three months ended September 30, 2026, compared to $44.9 million for the same period in 2025.
  • Net loss per common stock share, basic and diluted, was $(0.28) for the three months ended September 30, 2026, compared to $(0.44) for the same period in 2025.
  • Cash, cash equivalents and short-term investments were $299.4 million as of September 30, 2026.

Guidance

  • The Company expects that its cash position as of September 30, 2026, will enable it to fund its operating plan into the first quarter of 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →